Form 4: Apyx Medical Corp Director Craig A. Swandal Acquires 17,000 Stock Options
SEC Form 4 Filing
Director Craig A. Swandal acquired 17,000 stock options in Apyx Medical Corp on August 8, 2024, as part of the Director Compensation Program.
Summary
- Craig A. Swandal, a director of Apyx Medical Corp, acquired 17,000 stock options on August 8, 2024.
- The options have an exercise price of $1.02.
- These options were issued as part of the Issuer's Director Compensation Program.
- The options vest ratably over a 12-month period and become fully vested and exercisable on the first anniversary of the date of grant.
- Following the transaction, Swandal directly owns 17,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine transaction related to director compensation. The acquisition of stock options can be seen as a positive sign, but it's not a major event.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The stock options vest ratably over a 12-month period and become fully vested and exercisable on the first anniversary of the date of grant.
Industry Context
This filing is a routine disclosure related to director compensation, which is a common practice in publicly traded companies. It reflects standard corporate governance procedures.
Comparison to Industry Standards
- Director compensation packages, including stock options, are a common practice among publicly traded companies to align the interests of directors with those of shareholders.
- The vesting schedule of 12 months is fairly standard for stock option grants.
- Comparing the size of the grant (17,000 options) and the exercise price ($1.02) to similar companies in the medical device industry would provide a better understanding of the competitiveness of the compensation package.
Stakeholder Impact
- The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| June 25, 2024 | Date of Issuer's definitive proxy statement filed with the U.S. Securities and Exchange Commission, which provides for the issuance of a stock option to non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. |
| August 8, 2024 | Date of transaction: Craig A. Swandal acquired 17,000 stock options. |
| August 8, 2024 | Date the options become exercisable. |
| August 8, 2034 | Expiration date of the stock options. |
| August 12, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.